版本:
中国

BRIEF-Boston Scientific announces positive results from the Reprise III clinical trial

May 16 Boston Scientific Corp

* The Boston Scientific LOTUS™ valve system demonstrated superior efficacy to Corevalve® in global reprise III trial at one year

* Boston Scientific Corp says LOTUS valve system also demonstrated non-inferiority to corevalve platform for primary safety endpoint

* Boston Scientific - secondary endpoint demonstrated LOTUS valve system had lower rates of moderate to severe pvl occurrences compared to corevalve platform

* Boston Scientific Corp - LOTUS valve system showed superiority over corevalve tavi system platform for primary effectiveness endpoint Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐